The mission of The Leukemia & Lymphoma Society (LLS) is: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. We exist to find cured and ensure access to treatments for blood cancer patients. We are saving lives not somebody, but today. LLS is the world's largest voluntary health agency dedicated to blood cancer. LLS funds lifesaving blood cancer research around the world and provides free information and support services. Our key priorities will ensure that The Leukemia & Lymphoma Society helps blood cancer patients live better, longer lives.

Research - Through our research agenda, we advance the diagnosis and treatment of blood cancers through continued funding of academic research. Our Therapy Acceleration Program is a strategic initiative to partner with academic research institutions and biotechnology companies to get promising therapies to patients faster. Patient Services - LLS provides free information and support services to blood cancer patients and their families. Our Information Resource Center is a toll-free call center staffed with master's degree level healthcare professionals armed with up-to-date information about blood cancers and treatment options. The IRC fields approximately 60,000 inquiries a year and performs 6,000 clinical trials searches for patients. Our Co-Pay Assistance Program is designed to help patients afford their health insurance co-pays and insurance premiums. Since its inception in 2007 the co-pay program has provided $240 million in support and helped more than 55,000 patients. Our Patti Robinson Kaufmann program is a peer-to-peer program in which trained volunteer blood cancer survivors are matched with a newly diagnosed patient to share their experiences; and the Susan Lang Pay-it-Forward Travel Assistance Program helps patients with transportation/travel to help them get to their health care providers for their blood cancer related treatments. Policy and Advocacy - LLS is dedicated to removing barriers to care for blood cancer patients. Our policy and advocacy team works to secure both federal and state laws to ensure access, by limiting Out of pocket costs for treatments. For example, we have helped pass laws in 20 states ensuring equity in cost-sharing for thousands of patients who rely on orally-administered cancer treatments. LLS has played a critical role in advancing the 21st Century cures bill, designed to accelerate cures through FDA reform. LLS has built a nationwide grassroots network to empower blood cancer patients and their loved ones to affect real change in treatment and care through: currently more 100,000 grassroots advocates across the country. Human Resources - Top-grade all talent in LLS; hire, inspire and retain "A" talent for all positions. Transform the Human Resources department into a proactive service organization. Strengthen a performance-driven culture. Achieve "best in class" level HR processes from on-boarding to out-placement. Expand diversity from top to bottom. Finance - Minimize labor-intensive transactions and transaction processing. Greatly reduce staff time spent gathering, consolidating, forecasting and budgeting, actual and operational data. Provide analyses and predictive models that will help LLS solve problems, gain marketplace advantage, and support new initiatives.

We are the world's largest voluntary health agency dedicated to research specifically focused on finding cures and better treatments for blood cancer patients. We have 56 chapters throughout the United States and Canada. With the scope and scale to fund many projects at the same time, LLS supports hundreds of cancer scientists around the world and our network of chapter ensures that patients an families are served throughout the United States and Canada.

Our goal is a world without blood cancers. When survival rates for blood cancers improve and when we are reaching patients within the first 90 days of their diagnosis we will know we are getting closer to our goal.

LLS's research investment has played a critical role in advancing therapies for blood cancer patients, including targeted and immunotherapies. Five year survival rates have double, tripled and even quadrupled for some types of blood cancers. But more than 1/3 of blood cancer patients still do not live five years after diagnosis and we are determined to change that statistic.